Tristetraprolin induces cell cycle arrest in breast tumor cells through targeting AP-1/c-Jun and NF-κB pathway

Area of Science:

• Molecular Biology
• Oncology
• Cell Biology

Background:

• Cancer cell proliferation is a hallmark of malignancy, including breast cancer.
• The precise mechanisms of cancer cell proliferation, particularly those involving the RNA-binding protein tristetraprolin (TTP), require further elucidation.

Purpose of the Study:

• To investigate the role of tristetraprolin (TTP) in regulating breast cancer cell proliferation.
• To elucidate the molecular mechanisms by which TTP influences cell cycle progression and tumor growth.

Main Methods:

• In vitro cell proliferation assays and in vivo tumor growth suppression studies.
• Analysis of c-Jun and Wee1 expression levels.
• Investigation of TTP's effect on NF-κB p65 nuclear translocation and c-Jun transcription.
• Functional rescue experiments with NF-κB p65 and c-Jun.

Main Results:

• TTP inhibits breast cancer cell proliferation in vitro and suppresses tumor growth in vivo.
• TTP induces cell cycle arrest at the S phase by increasing Wee1 expression.
• TTP inhibits c-Jun transcription, independent of mRNA stability, by blocking NF-κB p65 nuclear translocation.
• Restoration of c-Jun negates TTP's inhibitory effects on proliferation.

Conclusions:

• TTP acts as a tumor suppressor by inhibiting c-Jun expression, leading to Wee1 induction, S-phase arrest, and suppressed proliferation.
• This study identifies a novel transcriptional regulatory pathway for TTP function.
• The TTP-mediated pathway represents a potential therapeutic target for breast cancer treatment.